



COLORADO

Department of Health Care
Policy & Financing

AGENDA
Pharmaceuticals & Therapeutics Committee
Department of Health Care Policy & Financing

Zoom Webinar:

https://magellanhealth.zoom.us/webinar/register/WN_-Lhjlt4rSqubZNYXQX4dQQ

Tuesday, April 12, 2022, 1:00-5:00 P.M.

1. Committee Member Introductions

2. Unfinished Business and General Orders

Approval of minutes from January 11, 2022 P&T meeting

Updates from January 11, 2022 P&T Meeting

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) - Oral & Non-Oral

Opioids - Short-Acting

Anticonvulsants, Oral

Newer Generation Antidepressants

Anti-Parkinson's Agents

Benzodiazepines (Non-Sedative Hypnotic)

Atypical Antipsychotics - Oral & Topical

Calcitonin Gene-Related Peptide Inhibitors (CGRPIs)

Triptans, Ditans and Other Migraine Treatments - Oral & Non-Oral

Skeletal Muscle Relaxants

Stimulants and Related Agents

Growth Hormones

Bile Salts

Multiple Sclerosis

Updates on Mass review drug classes:

Non-Opioid Analgesia Agents - Oral & Topical

Fentanyl Preparations

Opioids - Long-Acting

Alpha-Blockers

Beta-Blockers & Combinations

Calcium Channel Blockers

Lipotropics - Bile Acid Sequestrants, Fibrates, Other

Statins & Combinations

Monoamine Oxidase Inhibitors (MAOIs)

Tricyclic Antidepressants

Anxiolytics, Non-Benzodiazepine

Lithium Agents

Neurocognitive Disorder Agents

Sedative Hypnotics - Non-Benzodiazepine & Benzodiazepine

Improving health care equity, access, and outcomes for the people we serve while
saving Coloradans money on health care and driving value for Colorado.

www.colorado.gov/hcpf



Hemorrhoidal, Anorectal, and Related Topical Anesthetic Agents
 Ophthalmics, Allergy
 Ophthalmics, Immunomodulators
 Ophthalmics, Anti-Inflammatories
 Ophthalmics, Glaucoma

3. New Business

Review Sunshine Law/CORA
 Updates from the Prior Authorization Call Center

4. Drug Classes Up for Review

Review of Tetracyclines
 Review of Angiotensin Modifiers
 ACE Inhibitors, ARBs
 Review of PAH Therapies
 PDEIs, Endothelin Antagonists, Prostanoids & Guanylate Cyclase Stimulators
 Review of Statins & Combinations
 Review of Acne Agents, Topical
 Review of Anti-Psoriatrics
 Review of Immunomodulators, Topical
 Atopic Dermatitis, Antineoplastics & Other Agents
 Review of Topical Steroids
 Low, Medium, High & Very High Potency
 Review of Anti-Emetics
 Review of H. Pylori Treatments
 Review of Pancreatic Enzymes
 Review of Anticoagulants
 Review of Erythropoiesis Stimulating Agents
 Review of Benign Prostatic Hyperplasia (BPH) Agents

Mass review drug classes:

- Alpha-Blockers
- Beta-Blockers - Single Agent, Anti-Arrhythmics & Combinations
- Calcium Channel Blockers - DHPs & Non-DHPs
- Angiotensin Modifiers - Renin Inhibitors & Combinations
- Lipotropics - Bile Acid Sequestrants, Fibrates & Other Agents
- Acne Agents, Oral Isotretinoin
- Rosacea Agents
- Androgenic Agents - Topical, Injectable & Oral
- Bile Salts
- GI Motility, Chronic
- Hemorrhoidal, Anorectal, and Related Topical Anesthetic Agents

Improving health care equity, access and outcomes for the people we serve while
 saving Coloradans money on health care and driving value for Colorado.

www.colorado.gov/hcpf



- Proton Pump Inhibitors
- Non-Biologic Ulcerative Colitis Agents
- Anti-Platelets
- Colony Stimulating Factors
- Phosphate Binders

Each Review will contain:

- Oral presentation by manufacturers, providers, and public
- Overview for each Drug Class, including market share overview
- Committee Discussion and Recommendations for each Class

Mass Review drug classes will only include:

- Overview for each Drug Class, including market share overview

Presentations:

- Interested parties who want to present at the meeting shall give advanced notice and provide a one-page summary of the clinical testimony that will be presented for P&T Committee dissemination.
- Advance notice requests to present and/or written public comments can be submitted to Jessica Czechowski, Pharmacist Account Executive, jlczechowski@magellanhealth.com and carbon copy: Brittany Schock, PDL Pharmacist, brittany.schock@state.co.us. Once approved, public comments will be distributed to P&T Committee Members.
- Due to Virtual venue change, requests and public comment summaries are due by **March 31st, 2022 by 5pm MST.**

5. Adjourn

Upcoming Meeting Date: July 12, 2022.

Reasonable accommodations will be provided upon request. Auxiliary aids and services for individuals with disabilities and language services for individuals whose first language is not English may be provided upon request. Please notify the [504/ADA Coordinator](#) or hcpf504ada@state.co.us at least one week prior to the meeting to make arrangements.

